| abstract |
Novel crystalline forms of (R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(l-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-l-heptanoic acid hemi calcium salt designated form I, form II, and form IV are characterized by their X-ray powder diffraction and/or solid state NMR are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia and hypercholesterolemia. |